EN
CN EN
About Us
Innovative pharmaceutical high-tech company
Scroll Down
About Accropeutics

Accropeutics has developed a robust portfolio of innovative compounds spanning from lead optimization to clinical trials. The company's RIPK1 inhibitor AC-003 has completed the Phase I clinical trial in China and the United States in August 2023 and achieved positive results, and the clinical trial for aGvHD patients is currently undergoing. The Company's RlPK2 inhibitor AC-101 has completed the Phase I clinical trial in Australia demonstrating an outstanding safety and PK/PD profile. AC-201, a selective TYK2/JAK1 inhibitor with "Pipeline-in-a-Product" potential for treating inflammatory and autoimmune diseases, has completed the Phase I trial in Australia and China, and is currently in Phase II clinical trial for patients with moderate to severe plaque psoriasis. The Company has multiple compounds in the PCC and preclinical research stages. The Company owns global rights of all its assets with more than 10 patents issued in major markets including the US, the EU, China, Japan, and Korea.

Scientific Advisory Board
Dr. Henri Nico Doods
Chief Strategy Advisor

Dr. Henri Nico Doods was Senior Vice President of Boehringer Ingelheim and Global Head of Boehringer Ingelheim Research Beyond Border.

Dr. Doods has nearly 30 years of experience in pharmaceutical research and development, covering cardiovascular, pain, obesity, neurological, respiratory and other fields. He published more than 135 papers, and advanced more than 15 compounds into clinical development, including nintedanib (Ofev), the standard of care for the treatment of IPF. He received a Ph.D. degree is from University of Amsterdam.

Milestone
2024
2023
2022
2021
2017
Apr. 29, 2024

AC-201 First in Patient in China for Phase II in Psoriasis

Jul.25, 2024

AC-003 First in Patient in China for Phase Ib in aGVHD

2024
Mar. 2, 2023

AC-101 clinical trial was approved (HREC)

Apr. 12, 2023

AC-101 first in human in AUS

May. 4, 2023

AC-003 clinical trial for GVHD was approved (NMPA)

Jun. 21, 2023

AC-101 IND Approval (NMPA)

Jun. 26, 2023

AC-201 first in human in AUS

Sep. 8, 2023

AC-201 IND Approval (NMPA)

Nov. 29, 2023

AC-201 first in human in China

Dec. 11, 2023

AC-003 has been granted ODD by the FDA

2023
Apr. 16, 2022

AC-003 first in human in the US

Aug. 4, 2022

AC-003 IND Approval (NMPA)

Oct. 26, 2022

AC-003 first in human in China

2022
Dec. 1, 2021

Series B Financing

Dec. 23, 2021

AC-003 IND Approval (FDA)

2021
Sep. 2017

Series A Financing

Dec. 21, 2017

Found Accro Bioscience (Suzhou) Limited

2017
Investors

For investor relations related matters, please contact us at info@accropeutics.com

Morningside Ventures
Hongtai Aplus
South China Venture Capital
Shengzhou Capital Goup
Oriza Holdings